TUESDAY, Nov. 1, 2022 (HealthDay News) -- Among individuals with end-stage renal disease (ESRD), psoriasis is not associated with an increased risk for myocardial infarction (MI), according to a study recently published in the American Journal of the Medical Sciences.
Naomi Siddiquee, from the Medical College of Georgia at Augusta University, and colleagues used the United States Renal Data System to identify 1.06 million patients with ESRD starting dialysis between 2004 and 2015.
The researchers report that in the whole cohort, 0.6 percent of individuals had psoriasis and 17.1 percent had MI. However, among the 6,823 patients with psoriasis, 24 percent developed an MI. In unadjusted models, psoriasis was associated with an increased risk for MI (odds ratio, 1.34; 95 percent confidence interval, 1.26 to 1.42), but when controlling for demographics, dialysis modality, access type, and comorbidities, psoriasis was not associated with MI (odds ratio, 0.95; 95 percent confidence interval, 0.89 to 1.01).
"Contrary to prior research in the general population, in the ESRD population, psoriasis was not associated with an increased risk of MI after controlling for various demographic and clinical parameters," the authors write. "These data emphasize the importance of an integrated approach since comorbidities may influence the choice of therapy for psoriasis and outcomes."